Medscape

Preferred First-Line Treatment for C difficile Diarrhea Has Worse Outcome, Higher Costs

April 5, 2007 (Munich, Germany) — A database comparison of demographics, risk factors, and hospital outcomes for patients with Clostridium difficile–associated diarrhea (CDAD) shows that the preferred ...
ascopubs.org

Resolution of Clostridium difficile–Associated Diarrhea in Patients With Cancer Treated With Fidaxomicin or Vancomycin

Abbreviations: mITT, modified intent to treat; TTROD, time to resolution of diarrhea. *Comparing fidaxomicin and vancomycin. †Log-rank P = .0003, with versus without cancer. ‡Log-rank P = .145, with ...
Medscape

Fidaxomicin Beats Vancomycin for C difficile in Cancer

April 4, 2012 (London, United Kingdom) — Fidaxomicin (Dificid, Optimer Pharmaceuticals) treatment was superior to vancomycin for initial cure, recurrence, and sustained response, according to a ...
clinicaladvisor.com

Probiotics may ease C. difficile-associated diarrhea symptoms

LAS VEGAS — Potentially deadly antibiotic-associated Clostridium difficile-associated diarrhea (CDAD) affects 3 million Americans each year and is increasingly difficult to treat. Clinicians may want ...
clinicaladvisor.com

FDA warns of C. diff risk with PPIs

Health-care providers that treat patients who use proton pump inhibitors (PPI) and experience diarrhea that does not improve, should consider the bacterium Clostridium difficile in the differential ...
Reuters

FDA says ulcer drugs may raise diarrhea risk

Feb 8 (Reuters) - U.S. health regulators said ulcer drugs such as AstraZeneca Plc's blockbuster Nexium could increase the risk of clostridium difficile-associated diarrhea (CDAD). Clostridium ...